|
Topic |
Anxiety and Anxiety-Related Disorders (2 ACPE hours) ACPE #0284-0000-22-001-H01-P (Knowledge)
Author: Robin Hieber, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:
- Describe the signs and symptoms, diagnostic criteria, and pathophysiology for anxiety and anxiety-related disorders.
- Explain the use of common rating scales for research, diagnosis, and management of anxiety and anxiety-related disorders.
- Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of anxiety and anxiety-related disorders.
- Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in anxiety and anxiety-related disorders.
- Describe treatment guidelines, pharmacoeconomics, and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for anxiety and anxiety-related disorders.
- Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
- Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
- Describe the management of anxiety and anxiety-related disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
- Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with anxiety and anxiety-related disorders.
|
Biostatistics and Research Design in Psychiatry (2.5 ACPE hours) ACPE #0284-0000-22-002-H04-P (Knowledge)
Author: Ryan Carnahan, PharmD, MS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:
- Differentiate between descriptive and inferential statistics.
- Explain various study designs, including strengths and weaknesses, and types of bias present in each type.
- Describe appropriateness of the study design for research questions and hypotheses.
- Explain key epidemiologic concepts: incidence, prevalence, relative risk, odds ratio, relative and absolute risk reduction, and number needed to treat and harm.
- Explain the different types of error and how to reduce each.
- Explain the process of calculating a sample size.
- Describe different types of data, which statistical tests can be used for each type, groups being used, and the relationship between groups.
- Describe different ways to report and interpret statistical significance of a study using p-values and confidence intervals.
- Describe survival analyses.
- Outline the differences between noninferiority and traditional hypothesis testing trials.
- Describe the differences between internal and external validity.
- Discuss the differences between clinical and statistical significance.
- Explain the unique, core components of a pharmacoeconomic evaluation.
- Describe the differences between the four primary perspectives from which a pharmacoeconomic evaluation can be conducted.
- Contrast four economic evaluation methods commonly applied to pharmacy practice in today's healthcare settings, including the different outcomes that are employed by each method.
- Describe an incremental cost-effectiveness ratio.
- Distinguish between a systematic review and a meta-analysis.
- Describe the process of using a systematic approach to critically evaluating the literature.
|
Bipolar Disorder (1.5 ACPE hours) ACPE #0284-0000-22-003-H01-P (Knowledge)
Author: Jeremy Daniel, PharmD, BCPS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:
Describe the signs, symptoms, diagnostic criteria, and pathophysiology for bipolar disorder.
Explain the use of common rating scales for research, diagnosis, and management of bipolar disorder.
Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products) in the acute and long-term management of bipolar disorder.
Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, pharmacogenetic properties, adverse events, significant drug interactions, and warnings/precautions for drugs used in bipolar disorder.
Describe treatment guidelines, pharmacoeconomics, and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for bipolar disorder.
Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
Describe the management of bipolar disorder in special populations (i.e., pregnancy/lactation, children, and elderly).
Identify essential information to discuss during patient education about drug therapy.
|
Depression (1.5 ACPE hours) ACPE #0284-0000-22-004-H01-P (Knowledge)
Author: Sarah Grady, PharmD, BCPS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:
Describe the signs and symptoms, diagnostic criteria, and pathophysiology for depression.
Explain the use of common rating scales for research, diagnosis, and management of depression.
Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of depression.
Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in depression.
Describe treatment guidelines, pharmacoeconomics, and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for depression.
Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
Describe the management of depression in special populations (e.g., pregnancy/lactation, children, and elderly).
Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with depression.
Explain the components of suicide risk assessment.
Describe the determination of levels of suicide risk.
|
Introduction to Psychiatric Pharmacy (0.5 ACPE hours) ACPE #0284-0000-22-005-H04-P (Knowledge)
Author: Carol Ott, PharmD, BCPP, Chris Paxos, PharmD, BCPP, BCPS, BCGP
Learning Objectives
At the end of this program, the participant should be able to:
Identify social and cultural norms that can impact therapeutic outcomes.
List the essential components of the psychiatric interview and a neurologic evaluation.
Explain the role of the psychiatric interview in the collection of health and medication history.
Recognize the essential components of shared decision making and its importance to optimized patient outcomes.
Describe the principles and components of a holistic treatment approach.
Explain the rationale for collection of collateral information by the treatment team.
Outline the steps in the medication reconciliation process.
Describe the features of care coordination and transitional care models of care and the role of the pharmacist in these processes.
Identify principles and methods for educating health care professionals.
Explain procedures for assessing the effectiveness of education of health care professionals.
Identify principles and methods for educating patients and the public.
Explain procedures for assessing the effectiveness of education of patients and the public.
Identify principles of health literacy.
Outline principles, processes and measures for measuring the effectiveness of psychiatric pharmacy services.
Outline known disparities in psychotropic medication use on the basis of ethnicity, gender/gender identity, and geographic location.
Identify pharmacist practice models that address known gaps in care of psychiatric disorders.
Identify methods to provide and assess medication education to patients, families, and caregivers in individual and group sessions, and improve adherence.
|
Neurocognitive Disorders (1 ACPE hour) ACPE #0284-0000-22-006-H01-P(Knowledge)
Author: Andrew Williams, PharmD, BCPP, BCGP
Learning Objectives
At the end of this program, the participant should be able to:
Describe the signs and symptoms, diagnostic criteria, and pathophysiology for neurocognitive disorders.
Explain the use of common rating scales for research, diagnosis, and management of neurocognitive disorders.
Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of neurocognitive disorders.
Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in neurocognitive disorders.
Describe treatment guidelines, pharmacoeconomics, and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for neurocognitive disorders.
Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with neurocognitive disorders.
|
Neurodevelopmental, Disruptive, Impulse-Control and Conduct Disorders (1 ACPE hour) ACPE #0284-0000-22-007-H01-P (Knowledge)
Author: Sandra Mullen, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:
Describe the signs and symptoms, diagnostic criteria, and pathophysiology for neurodevelopmental, disruptive, impulse-control, and conduct disorders.
Explain the use of common rating scales for research, diagnosis, and management of neurodevelopmental, disruptive, impulse-control, and conduct disorders.
Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of neurodevelopmental, disruptive, impulse-control, and conduct disorders.
Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in neurodevelopmental, disruptive, impulse-control, and conduct disorders.
Describe treatment guidelines, pharmacoeconomics, and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for neurodevelopmental, disruptive, impulse-control, and conduct disorders.
Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
Describe the management of neurodevelopmental, disruptive, impulse-control, and conduct disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
Recognize the behavioral phenotypes, major medical complications, risk factors, pathogenesis, clinical course, and drug therapy treatment options for patients with the following syndromes:
Down Syndrom
Prader-Willi Syndrome
Fragile X Syndrome
Klinefelter’s Syndrome
Rett's Syndrome
- Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with neurodevelopmental, disruptive, impulse-control, and conduct disorders.
|
Neurologic Disorders (2.5 ACPE hours) ACPE #0284-0000-22-008-H01-P (Knowledge)
Author: Kimberly Tallian, PharmD, APH, BCPP, FASHP, FCCP, FCSHP
Learning Objectives
At the end of this program, the participant should be able to:
Describe the signs and symptoms, diagnostic criteria, and pathophysiology for neurologic disorders.
Explain the use of common rating scales for research, diagnosis, and management of neurologic disorders.
Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of neurologic disorders.
Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, boxed warnings, and Risk Evaluation and Mitigation Strategies (REMS) programs) for drugs used in neurologic disorders.
Describe treatment guidelines, pharmacoeconomics, and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for neurologic disorders.
Recognize an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
Describe the management of neurologic disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with neurologic disorders.
|
Personality Disorders and Eating Disorders (0.5 ACPE hours) ACPE #0284-0000-22-009-H01-P (Knowledge)
Author: Lindsey Miller, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:
Describe the signs and symptoms, diagnostic criteria, and pathophysiology for personality disorders and eating disorders.
Explain the use of common rating scales for research, diagnosis, and management of personality disorders and eating disorders.
Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of personality disorders and eating disorders.
Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in personality disorders and eating disorders.
Describe treatment guidelines, pharmacoeconomics, and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for personality disorders and eating disorders.
Recognize an evidence-based drug therapy regimen (i.e., drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
Describe the management of personality disorders and eating disorders in special populations (e.g., pregnancy/lactation, children, and elderly). - Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with personality disorders and eating disorders.
|
Regulatory Issues in Pharmacy Practice (2 ACPE hours) ACPE #0284-0000-22-010-H04-P (Knowledge)
Author: Michele Thomas, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:
Describe the P&T Committee, formulary management, medication use evaluation (MUE), and the MUE process from identification of drug to development and implementation of protocols or guidelines.
Outline a plan to start a new service or evaluate a current service using the performance improvement cycle.
Outline a program to monitor and prevent medication misadventures.
Recognize the Joint Commission standards related to pharmacy practice in psychiatric settings.
Describe the use of State Operations Manual F-tags in the pharmacologic management of psychiatric disorders in long-term care facilities.
Explain the basic ethical principles of the Belmont Report and its relationship to human subject research and clinical practice.
Describe the roles of the institutional review board, U.S. Department of Health and Human Services, and Office for Human Research Protections in research that impact patients with psychiatric illness.
Describe the role of Centers for Medicare and Medicaid Services in the reimbursement process for healthcare, including pharmacy.
Describe steps to be taken for compliance with the Drug Supply Chain Security Act.
Describe the safe handling of hazardous medications in psychiatric settings as defined by USP General Chapter <800>.
Apply principles of professional ethics to the issue of medication administration in patients that lack capacity to provide consent.
Describe the characteristics of prescription drug monitoring programs.
Discuss the evidence for the effectiveness of prescription drug monitoring programs.
Describe disease surveillance and the national and international organizations that report on it.
Define collaborative practice agreements and the common components of their regulations.
State the roles of professionals involved in collaborative practice agreements and strategies for developing agreements.
Describe resources available to pharmacists for the development of collaborative practice agreements.
|
Schizophrenia Spectrum and Other Psychotic Disorders (2 ACPE hours) ACPE #0284-0000-22-011-H01-P (Knowledge)
Author: Charles Caley, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:
Describe the signs and symptoms, diagnostic criteria, and pathophysiology for schizophrenia spectrum, other psychotic disorders, and movement disorders.
Explain the use of common rating scales for research, diagnosis, and management of schizophrenia spectrum, other psychotic disorders, and movement disorders.
Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of schizophrenia spectrum, other psychotic disorders, and movement disorders.
Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in schizophrenia spectrum, other psychotic disorders, and movement disorders.
Describe treatment guidelines, pharmacoeconomics, and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for schizophrenia spectrum, other psychotic disorders, and movement disorders.
Recognize an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
Describe the management of schizophrenia spectrum, other psychotic disorders, and movement disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with schizophrenia spectrum, other psychotic disorders, and movement disorders.
Describe provider behaviors and responses, environmental responses, and de-escalation techniques useful for calming agitated patients.
|
Sleep-Wake Disorders (1.5 ACPE hours) ACPE #0284-0000-22-012-H01-P (Knowledge)
Author: Megan Maroney, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:
Describe the signs and symptoms, diagnostic criteria, and pathophysiology for sleep-wake disorders.
Explain the use of common rating scales for research, diagnosis, and management of sleep-wake disorders.
Discuss the efficacy of pharmacologic and non-pharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of sleep-wake disorders.
Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions [including medical comorbidities, black box warnings, and risk evaluation and mitigation strategy (REMS) programs] for drugs used in sleep-wake disorders.
Describe treatment guidelines, pharmacoeconomics, and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for sleep-wake disorders.
Recognize an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
Describe the management of sleep-wake disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with sleep-wake disorders.
|
Substance-Related Disorders (1.5 ACPE hours) ACPE #0284-0000-22-013-H01-P (Knowledge)
Author: Erika Titus-Lay, PharmD, BCPS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:
Describe the signs and symptoms, diagnostic criteria, and pathophysiology for substance-related disorders.
Explain the use of common rating scales for research, diagnosis, and management of substance-related disorders.
Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of substance-related disorders.
Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in substance-related disorders.
Describe treatment guidelines, pharmacoeconomics, and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for substance-related disorders.
Recognize an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
Describe the management of substance-related disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with substance-related disorders.
|
Whether a certification candidate or a currently certified individual, the goal of the Review Course is to assist the practitioner in developing and maintaining contemporary knowledge and skills at the psychiatric pharmacy specialty level. The Review Course is not designed to develop more in-depth "subspecialty" knowledge. Course content is structured to provide a comprehensive review of the three psychiatric pharmacy domains specified by the Specialty Council in the current edition of the BPS Candidate's Guide. Inclusion of the Review Course as part of the recertification program is critical in ensuring the BCPP has systematically reviewed and assessed his/her core knowledge in the psychiatric specialty practice. This course is a knowledge-based educational program designed for pharmacists to acquire factual knowledge.
The American Association of Psychiatric Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The 2022-2023 Psychiatric Pharmacotherapy Review Course is a knowledge-based course and will provide 20 hours (2.0 CEUs) of continuing education credit. Additionally, the 2022-2023 Psychiatric Pharmacotherapy Review Course will provide 20 hours of BCPP Recertification credit. BCPP Recertification credit is earned and reported within the year the assessment is successfully completed.